[ad_1]
The “Plasma Derived Medicine Market, by Product Type, by Indication, by Distribution Channel, and by Region – Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028” report has been added to ResearchAndMarkets.com’s offering.
Plasma-derived medicinal products are pharmaceuticals or medicines produced from human plasma which is the liquid portion of the blood and consists of approximately 90% water. It contains over 120 different proteins that take on functions vital to life, such as fighting infections or clotting of blood to stop bleeding after an injury.
Albumin, immunoglobulin, clotting factors, fibrinogens, and other plasma-derived medicinal compounds can be extracted from plasma. PDMPs (plasma-derived medicinal products) are used in medical treatment and prophylaxis. Plasma products play an important role in managing autoimmune disorders, bleeding emergencies, and a number of chronic conditions such as hemophilia, congenital and acquired immunodeficiencies, and other inherited protein disorders.
Increasing product approvals by regulatory bodies for plasma-derived medicines are expected to drive the global plasma derived medicine market over the forecast period. For instance, in July 2021, Octapharma AG, a company that develops and produces high-quality human proteins from human plasma and human cell lines, announced that the US Food and Drug Administration (FDA) had granted approval for its Octagam 10%, …
Full story available on Benzinga.com
[ad_2]
Source link
